Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Cited by (999)

Items 501–600 of 999

1. Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study
   Mehmet Cem Sabaner, Reşat Duman, Mustafa Doğan, Müberra Akdoğan, Ayhan Vurmaz, Erhan Bozkurt, Selvihan Beysel · 2021 · Journal Français d Ophtalmologie
2. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
   David Aristizábal-Colorado, Martín Ocampo-Posada, Wilfredo Antonio Rivera Martínez, David Corredor-Rengifo, Jorge E. Rico-Fontalvo, Juan Esteban Gómez‐Mesa, John Jairo Duque Ossman, Alín Abreu-Lomba · 2024 · American Journal of Cardiovascular Drugs
3. Renal Effects of Antisense-Mediated Inhibition of SGLT2
   Leonie van Meer, Matthijs Moerland, Marloes van Dongen, Bas Goulouze, Marieke de Kam, Erica Surya Klaassen, Adam F. Cohen, Jacobus Burggraaf · 2016 · Journal of Pharmacology and Experimental Therapeutics
4. Sodium bicarbonate loading limits tubular cast formation independent of glomerular injury and proteinuria in Dahl salt-sensitive rats
   Sarah R. McLarnon, Bansari Patel, Debra Lima Irsik, Jingping Sun, Hiram Ocasio, Gene Ryan Crislip, Chunhua Jin, Jian‐Kang Chen, Babak Baban, Aaron James Polichnowski et al. · 2018 · Clinical Science
5. Unexplained reciprocal regulation of diabetes and lipoproteins
   Sei Higuchi, María Concepción Izquierdo, Rebecca A. Haeusler · 2018 · Current Opinion in Lipidology
6. Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients—A Narrative Review
   Rohini Garg, Nikhil Sood, Ojas Bansal, Abhinav Hoskote · 2024 · Journal of General Internal Medicine
7. Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review
   Roxana Daniela Brata, Andrei Vasile Paşcalău, Ovidiu Frățilă, Ioana Larisa Paul, Mihaela Mirela Muresan, Andreea Cămărășan, Tiberia Ioana Ilias · 2024 · Healthcare
8. SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes
   Qian Wu, Jian Zhang, Fuli Zhang, Dongnan Li · 2025 · Frontiers in Endocrinology
9. Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
   Adriana Dana Oprea, Basma A. Mohamed, David L. Hepner, Moisés Auron, Deborah C. Richman, Guillermo E. Umpierrez, Daniel L. Edmonston, Costin Ionescu, Mandeep Kumar, BobbieJean Sweitzer · 2026 · British Journal of Anaesthesia
10. Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
    Charlotte C. van Ruiten, Dick J. Veltman, Madelief Wijdeveld, Jennifer S. ten Kulve, Mark H.H. Kramer, Max Nieuwdorp, Richard G. IJzerman · 2022 · Diabetes Obesity and Metabolism
11. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease
    Takahiro Masuda, Daisuke Nagata · 2023 · Hypertension Research
12. Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung‐Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol‐Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim et al. · 2023 · Diabetes & Metabolism
13. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
    Bassel Al-Hindi, Mohammed A. Mohammed, Ernest Mangantig, Nataly Dominica Martini · 2023 · Journal of the American Pharmacists Association
14. The EMPA-REG outcome study: critical appraisal and potential clinical implications
    Gianluca Perseghin, Anna Solini · 2016 · Cardiovascular Diabetology
15. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice
    Kuralay K. Atageldiyeva, Yukihiro Fujita, Tsuyoshi Yanagimachi, Katsutoshi Mizumoto, Yasutaka Takeda, Jun Honjo, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Masakazu Haneda · 2016 · PLoS ONE
16. A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
    Ashley M. Zurek, Raghunandan Yendapally, Elizabeth M. Urteaga · 2017 · Diabetes Spectrum
17. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
    Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal · 2020 · Advances in experimental medicine and biology
18. Sodium–glucose cotransporter 2 inhibitors improved time‐in‐range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single‐center, pilot study
    Daisuke Suzuki, Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Misato Amamoto, Jun Morimoto, Kazuo Hara · 2020 · Journal of Diabetes Investigation
19. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure
    Kayla A. Riggs, Hiba Ali, Heinrich Taegtmeyer, Absalon Gutierrez · 2015 · Metabolic Syndrome and Related Disorders
20. Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?
    Magnus F.G. Grøndahl, Damien J. Keating, Tina Vilsbøll, Filip Krag Knop · 2017 · Current Diabetes Reports
21. Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases
    Sebastian Steven, Marin Kuntić, Thomas F. Münzel, Andreas Daiber · 2025 · Pharmacological Reviews
22. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
    David R. Powell, Deon D. Doree, Sabrina L. Jeter-Jones, Zhi‐Ming Ding, Brian Zambrowicz, Arthur Sands · 2015 · Diabetes Metabolic Syndrome and Obesity
23. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
    Michaela Luconi, Laura Raimondi, A. Di Franco, Edoardo Mannucci · 2016 · Nutrition Metabolism and Cardiovascular Diseases
24. Practical combination therapy based on pathophysiology of type 2 diabetes
    PHILIP A. LEVIN · 2016 · Diabetes Metabolic Syndrome and Obesity
25. Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice
    Bingxian Xie, Wesley Ramirez, Amanda M. Mills, Brydie R. Huckestein, Moira Anderson, Martha M. Pangburn, Eric Y. Lang, Steven J. Mullett, Byron W. Chuan, Lanping Guo et al. · 2022 · Current Research in Physiology
26. Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
    Muhammad Shahzeb Khan, Izza Shahid, Stephen John Greene, Robert John Mentz, Adam D. DeVore, Javed Butler · 2022 · Cardiovascular Research
27. Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
    Chung-An Wang, Li‐Chun Lin, Jui‐Yi Chen, Wei-Jie Wang, Vin‐Cent Wu · 2024 · Cardiovascular Diabetology
28. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
    Esther Kim, Emma D. Deeks · 2015 · Drugs
29. SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice
    Michael J. Jurczak, Saumya Saini, Simona Ioja, Diana K. Costa, Nnamdi Udeh, Xiaojian Zhao, Jean M. Whaley, Richard Glenn Kibbey · 2018 · Islets
30. Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
    ManashPratim Baruah, B. M. Makkar, VikrantB Ghatnatti, Kaushik Mandal · 2019 · Indian Journal of Endocrinology and Metabolism
31. The effect of circuit resistance training, empagliflozin or “vegeterranean diet” on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial)
    Assaf Buch, Roy Eldor, Ofer Kis, Lital Keinan‐Boker, Ayelet Dunsky, Amir Rubin, Adar Lopez, Yael Sofer, Etty Osher, Yonit Marcus et al. · 2019 · BMC Geriatrics
32. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial
    Tao Yuan, Shixuan Liu, Yingyue Dong, Yong Fu, Yan Tang, Weigang Zhao · 2020 · Diabetology & Metabolic Syndrome
33. Antidiabetic Effect of S chisandrae C hinensis F ructus Involves Inhibition of the Sodium Glucose Cotransporter
    Yue Qu, Judy Yuet‐Wa Chan, Chun‐Wai Wong, Ling Cheng, Chuanshan Xu, Albert Wingnang Leung, Clara Bik‐San Lau · 2014 · Drug Development Research
34. Hepatic Gluconeogenic Response to Single and Long-Term SGLT2 Inhibition in Lean/Obese Male Hepatic G6pc-Reporter Mice
    Inaba, Yuka, Hashiuchi, Emi, Watanabe, Hitoshi, Kimura, Kumi, Sato, Makoto, Kobayashi, Masaki, Matsumoto, Michihiro, Kitamura, Tadahiro, Kasuga, Masato, Inoue, Hiroshi · 2019 · Endocrinology
35. Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
    Alessandro Cuttone, Vittorio Cannavò, Raouf Mastan Sheik Abdullah, Pierluigi Fugazzotto, Giada Arena, Simona Brancati, Andrea Muscarà, Carmela Morace, Cristina Quartarone, Domenica Ruggeri et al. · 2025 · Cells
36. SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
    David Feder, Marisa Regina de Fatima Veiga Gouveia, Tânia Carmen Peñaranda Govato, Cristina de Zotti Nassis · 2020 · Current Pharmacology Reports
37. Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function
    Akinobu Nakamura · 2022 · International Journal of Molecular Sciences
38. Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Pedro F. Monteiro, Carlos Aguíar, Pedro Lucas Pereira Matos, José Silva‐Nunes, Rita Birne, Patrícia Quadros Branco, Joaquim Calado, Miguel Melo, Jorge Junqueira Polónia · 2019 · Revista Portuguesa de Cardiologia (English Edition)
39. Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis
    Habib Yaribeygi, Mina Maleki, Fatemeh Sokouti Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2022 · Journal of Cellular Physiology
40. Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo · 2022 · Advances in Therapy
41. The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
    Rohani, Pejman, Malekpour Alamdari, Nasser, Bagheri, Seyedeh Elaheh, Hekmatdoost, Azita, Sohouli, Mohammad Hassan · 2023 · Frontiers in Endocrinology
42. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study
    Yun Kyung Cho, Kyung Soo Kim, Byung‐Wan Lee, Jun Hwa Hong, Jae Myung Yu, Soo Kyung Lim, Ye An Kim, Chang Beom Lee, Sang Soo Kim, Soo Heon Kwak et al. · 2024 · Clinical Therapeutics
43. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes
    Xueying Tan, Jingbo Hu · 2016 · Annales d Endocrinologie
44. Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: A n exploratory mechanistic study
    Thomas M. Forst, Alexander C. Falk, Grit Andersen, Annelie Fischer, Matthias M. Weber, Stephan Voswinkel, Tim Heise, Christoph Kapitza, Leona Plum‐Mörschel · 2016 · Diabetes Obesity and Metabolism
45. Glucose effectiveness is a critical pathogenic factor leading to glucose intolerance and type 2 diabetes: An ignored hypothesis
    FRANK P. ALFORD, Jan Erik Henriksen, Christian Rantzau, Henning Beck‐Nielsen · 2018 · Diabetes/Metabolism Research and Reviews
46. Dapagliflozin restores insulin and growth hormone secretion in obese mice
    Zhengxiang Huang, Lili Huang, Chengjian Wang, Shanli Zhu, Xinzhou Qi, Yang Chen, Yanjun Zhang, Michael Alexander Cowley, Johannes D. Veldhuis, Chen Chen · 2020 · Journal of Endocrinology
47. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
    Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens Juul Holst, Filip Krag Knop, Tina Vilsbøll · 2020 · Diabetes
48. Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer
    Vivek R. Bora, Bhoomika M. Patel · 2021 · Life Sciences
49. Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes
    Caroline Kaercher Kramer, Bernard Zinman, Haysook Choi, Ravi R. Retnakaran · 2015 · The Journal of Clinical Endocrinology & Metabolism
50. Circulating SerpinB1 levels and clinical features in patients with type 2 diabetes
    Kohzo Takebayashi, Kenji Hara, Tomoko Terasawa, Rika Naruse, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inukai · 2016 · BMJ Open Diabetes Research & Care
51. Canagliflozin-Induced Diabetic Ketoacidosis
    Jessica Turner, Tahmina Begum, Roger D. Smalligan · 2016 · Journal of Investigative Medicine High Impact Case Reports
52. SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
    Elamin Abdelgadir, Fouzia Rashid, Alaaeldin M. Bashier, Razan Ali · 2018 · Journal of Clinical Medicine Research
53. Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation
    Tomoko Yamada, Kazuhiko Sakaguchi, Yuko Okada, Hiroshi Miura, Natsu Otowa‐Suematsu, Anna So, Hisako Komada, Yushi Hirota, Takeshi Ohara, Yasuo Kuroki et al. · 2020 · Diabetology International
54. Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
    Vaneza Lira Waldow Wolf, Ikaro Soares Santos Breder, Luiz Sérgio Fernandes de Carvalho, Alexandre Soares, Riobaldo M.R. Cintra, Joaquim Barreto, Daniel Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra‐Júnior et al. · 2021 · Nutrition and Diabetes
55. Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
    Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow, Corina T. Madreiter‐Sokolowski · 2022 · Frontiers in Aging
56. Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial
    Ele Ferrannini, Anna Solini, Simona Baldi, Tiziana Scozzaro, David Polidori, Andrea Natali, Michael K. Hansen · 2023 · Diabetes
57. Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
    Vincent C. Woo · 2015 · International Journal of Clinical Practice
58. Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
    Karen S.L. Lam, Chun Chung Chow, K. C. B. Tan, Ronald C.W., Alice P.S. Kong, Peter C.Y. Tong, Man Wo Tsang, Tak Mao Chan, Sydney C.W. Tang, Ka Kui Lee et al. · 2016 · Current Medical Research and Opinion
59. Personalized Therapy by Phenotype and Genotype
    Valeriya Lyssenko, Cristina Bianchi, Stefano Del Prato · 2016 · Diabetes Care
60. Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions
    John A. D’Elia, Alissa R. Segal, George P Bayliss, Larry A. Weinrauch · 2017 · International Journal of Nephrology and Renovascular Disease
61. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Myint Aung Moh Moh, Chan‐Hee Jung, Bora Lee, Dughyun Choi, Bo‐Yeon Kim, Chul‐Hee Kim, Sung‐Koo Kang, Ji‐Oh Mok · 2018 · Diabetes and Vascular Disease Research
62. Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
    Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, TAEKO OSAWA, Kazuo Furukawa, Hiroshi Suzuki, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku, Hirohito Sone · 2020 · Diabetes Obesity and Metabolism
63. Cardiovascular benefit of SGLT2 inhibitors
    Reza Mohebi, James L. Januzzi · 2021 · Critical Reviews in Clinical Laboratory Sciences
64. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
    Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, Vasilis Tsimihodimos, Fisseha Tesfaye, Wayne C. Shaw, Norman R Rosenthal, Gemma A. Figtree, Bruce Charles Neal, Kenneth W. Mahaffey et al. · 2022 · Diabetes Care
65. The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review
    Stewart, Paul A., Nestor, Claire C., Clancy, Cillian, Irwin, Michael G. · 2025 · Anaesthesia
66. The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol
    Kristien E. C. Bouter, Erik J.M. van Bommel, Hans Jansen, Dewi van Harskamp, Henk Schierbeek, Mariëtte T. Ackermans, Mireille J. M. Serlie, Alinda W.M. Schimmel, Max Nieuwdorp, Geesje M. Dallinga‐Thie et al. · 2020 · Diabetes Obesity and Metabolism
67. SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes
    SCHAFER C. BOEDER, Justin M. Gregory, Erin R. Giovannetti, Jeremy Pettus · 2021 · Diabetes
68. Management of Hyperglycemia in Older Adults with Type 2 Diabetes
    Gunjan Yogendra Gandhi, Arshag D. Mooradian · 2021 · Drugs & Aging
69. The DAPA‐DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity—A longitudinal cohort study
    Petra Hanson, Harpal Singh Randeva, Dan J Cuthbertson, Paul J. O'Hare, Nick Parsons, Kamaljit Kaur Chatha, Gemma Reidy, Martin O. Weickert, Thomas M. Barber · 2022 · Endocrinology Diabetes & Metabolism
70. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis
    Tao Liu, Zeyuan Fan, Bing Xiao, He Chang, Shicong Wang · 2024 · Cardiovascular Diabetology
71. Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction
    Chen Gao, Zhaojun Xiong, Yunxia Liu, Meng Wang, Menglong Wang, Tian Liu, Jianfang Liu, Shuxun Vincent Ren, Nancy Cao, Hai Yan et al. · 2024 · Circulation Research
72. Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
    В. В. Салухов, Tatiana Yu. Demidova · 2016 · Diabetes Mellitus
73. Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Keiichi Torimoto, Yosuke Okada, Kenji Koikawa, Yoshiya Tanaka · 2017 · Diabetology & Metabolic Syndrome
74. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
    Eugênio Cersósimo, John M. Miles · 2018 · Current Diabetes Reviews
75. Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
    Shuichi Nagashima, Tetsuji Wakabayashi, Naoko Saito, Manabu Takahashi, Kenta Okada, Ken Ebihara, Shun Ishibashi · 2020 · Journal of Diabetes Investigation
76. Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes—a case series and literature review
    Adnan Zaina, Yuval Grober, Abid Ali, Eldad Arad, Elena Golden, Samih Badarny · 2021 · Endocrine
77. Sodium‐glucose cotransporter‐2 inhibitors and non‐steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin‐angiotensin system blockade
    Srinivas Vinayak Shenoy, Shankar Prasad Nagaraju, Mohan Varadanayakanahalli Bhojaraja, Ravindra Prabhu, Dharshan Rangaswamy, Indu Ramachandra Rao · 2021 · Nephrology
78. Glycaemic variabilities: Key questions in pursuit of clarity
    Louis Monnier, David R. Owens, C Colette, Fabrice Bonnet · 2021 · Diabetes & Metabolism
79. Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
    Chi‐Ho Lee, Mei‐Zhen Wu, David Tak Wai Lui, Darren Shing-Hei Chan, Carol Ho-Yan Fong, Sammy W.M. Shiu, Ying Wong, Alan Chun‐Hong Lee, Joanne K.Y. Lam, Yu Cho Woo et al. · 2022 · Diabetes & Metabolism Journal
80. Magnetic Resonance Imaging and Spectroscopy Methods to Study Hepatic Glucose Metabolism and Their Applications in the Healthy and Diabetic Liver
    Ayhan Gürsan, Jeanine J. Prompers · 2022 · Metabolites
81. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
    Roselle A. Herring, Fariba Shojaee‐Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, Anne Margot Umpleby, Melanie Jane Davies et al. · 2020 · Diabetes Care
82. Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
    Juan Guerrero‐Mauvecin, Natalia Villar-Gómez, Lucia Miño-Izquierdo, Adrián Povo‐Retana, Adrian Mario Ramos, Gema Ruiz‐Hurtado, María Dolores Sánchez-Niño, Alberto Ortíz, Ana Belen Sanz · 2025 · Antioxidants
83. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Robert M. Guthrie · 2015 · Postgraduate Medicine
84. Combination therapy with SGLT2 inhibitors for diabetic kidney disease
    Yuwen Cai, Xin Liu, Gaosi Xu · 2020 · Biomedicine & Pharmacotherapy
85. SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis
    Xingyun Zhu, Chu Lin, Li Li, Suiyuan Hu, Xiaoling Cai, Linong Ji · 2021 · European Journal of Pharmacology
86. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity
    Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2022 · European Journal of Pharmaceutical Sciences
87. Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression
    Adittya Arefin, Matthew Gage · 2023 · International Journal of Molecular Sciences
88. Oral sugar test responses to ertugliflozin in ten horses with insulin dysregulation
    Tania Sundra, Gabriele Rossi, Erin A. Kelty, Guy D. Lester, David I. Rendle · 2023 · Equine Veterinary Education
89. Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
    Minji Sohn, Seoungyeon Nam, Michael Albrecht Nauck, Soo Kyung Lim · 2024 · BMC Medicine
90. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations
    Li Geng, Bing Sun, Yan Chen · 2024 · Diabetes Obesity and Metabolism
91. SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
    Lance Alan Sloan · 2024 · Postgraduate Medicine
92. Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes
    Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Yumi Watanabe, Maki Gouda, Hiroaki Iijima · 2017 · Diabetes Obesity and Metabolism
93. Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
    Jiahua Li, Christopher O Fagbote, Min Zhuo, Chelsea E. Hawley, Julie M. Paik · 2019 · Clinical Kidney Journal
94. Dapagliflozin Does Not Directly Affect Human α or β Cells
    Chunhua Dai, John T. Walker, Alena Shostak, Yasir H. Bouchi, Greg Poffenberger, Nathaniel J. Hart, David Aaron Jacobson, M. Wade Calcutt, Rita Bottino, Dale L. Greiner et al. · 2020 · Endocrinology
95. Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM
    Ali Muhammed Ali, Andrea Mari, ROBERT A. MARTINEZ, Hussein Al Jobori, John M. Adams, Curtis L. Triplitt, Ralph A. DeFronzo, Eugênio Cersósimo, Muhammad A Abdul‐Ghani · 2020 · The Journal of Clinical Endocrinology & Metabolism
96. Innovative TLC-densitometric method with fluorescent detection for simultaneous determination of ternary anti-diabetic mixture in pharmaceutical formulations and human plasma
    Noha S. Abbas, Sayed M. Derayea, Mahmoud Ahmed Omar, Gamal A. Saleh · 2021 · Microchemical Journal
97. Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on P hase 3 trials 艾格列净治疗2型糖尿病：基于3期试验的安全性与有效性概述
    GEORGE E. DAILEY · 2015 · Journal of Diabetes
98. Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
    Awadhesh Kumar Singh, Ritu Singh · 2016 · Indian Journal of Endocrinology and Metabolism
99. Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus
    Alexandra Sophie Moss, Gerasimos Dimitropoulos, Derek Leslie Connolly, Gregory Y.H. Lip · 2017 · Expert Opinion on Pharmacotherapy
100. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
     Utkarsh Ojha, Lenisse M. Reyes, Florence Eyenga, Diane Oumbe, Justyna Watkowska, Henock Saint-Jacques · 2021 · American Journal of Cardiovascular Drugs